Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
| Brand name | METFORMIN HYDROCHLORIDE |
| Generic name | METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | Viona Pharmaceuticals Inc. Cranford, NJ 07016 |
| NDC | 72578-036-01 |
| Full product label | Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 Tablets, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India. Distributed by: Viona Pharmaceuticals Inc. Cranford, NJ 07016 NDC 72578-036-01 |
| Recalling firm | VIONA PHARMACEUTICALS INC |
| Distribution | Nationwide in the US |
| Quantity | 21240 bottles |
| Recall initiated | 2021-06-01 |
| Report date | 2021-06-30 |
| Recall completed | 2023-05-31 |
| Recall number | D-0640-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Cranford NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗